PTCT PTC Therapeutics, Inc.

14.16
+0.38  (2.76%)
Previous Close 13.78
Open 13.93
Price To book 3.36
Market Cap 483.78M
Shares 34,165,000
Volume 1,111,866
Short Ratio 4.83
Av. Daily Volume 799,684

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated October 2016. Phase 3 part of trial to commence in 2017.
RG7916
Spinal Muscular Atrophy (SMA)
Received a Refusal to File letter for their NDA Filing - February 23 2016. Appeal rejected October 17, 2016. Decision made to resubmit NDA during 1Q 2017 under protest.
Translarna
Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)
Phase 3 initiated July 2014. Enrolment completed November 2015. Data due late 1Q 2017.
Translarna
Nonsense mutation cystic fibrosis

Latest News

  1. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  2. Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100
  3. Is the Options Market Predicting a Spike in PTC Therapeutics (PTCT) Stock?
  4. PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
  5. PTC Therapeutics, Inc. – Value Analysis (NASDAQ:PTCT) : February 1, 2017
  6. PTC Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : PTCT-US : January 31, 2017
  7. Is the Options Market Predicting a Spike in PTC Therapeutics Stock?
  8. European Commission Ratifies Positive CHMP Opinion for the Renewal of Translarna™ Marketing Authorization for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy
  9. PTC THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F
  10. PTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna™ and Advance its Innovative Pipeline
  11. RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy
  12. RG7916 Granted Orphan Drug Designation in the U.S. for the Treatment of Spinal Muscular Atrophy
  13. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  14. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  15. PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients
  16. PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients
  17. PTC Therapeutics to Present 2017 Corporate Update at the 35th Annual J.P. Morgan Healthcare Conference
  18. Are Options Traders Betting on a Big Move in PTC Therapeutics (PTCT) Stock?
  19. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  20. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  21. PTC Therapeutics Receives France's 2016 Prix Galien for Translarna™
  22. PTC Therapeutics, Inc. in 3 Charts
  23. Is PTC Therapeutics, Inc. (PTCT) a Good Stock to Buy?
  24. Why PTC Therapeutics, Inc. Stock Rose 75.4% in November
  25. Why Small Stocks Are Fueling Giant Returns
  26. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  27. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  28. CHMP Recommends Renewal of Translarna's™ Marketing Authorization for Nonsense Mutation Duchenne Muscular Dystrophy Based on Continued Positive Benefit-Risk Assessment
  29. PTC Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
  30. Spinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies in SMA Patients with RG7916
  31. PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial Results
  32. PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy
  33. PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients
  34. New Research Validates Translarna's™ (ataluren) Mechanism of Action to Promote Readthrough of Nonsense Mutations and Produce Full-length Functional Protein
  35. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  36. PTC Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
  37. PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren)
  38. NHS England Enables Access to Translarna™ ▼ (ataluren) For Patients with Nonsense Mutation Duchenne Muscular Dystrophy
  39. PTC Therapeutics Appoints Dawn Svoronos to Board of Directors
  40. New Analyses from Phase 3 Study 009 of Translarna™ (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference
  41. PTC Therapeutics Announces Winners of the Global Cystic Fibrosis Patient Group Awards
  42. PTC Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
  43. Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources